HIV AND NOVEL STRATEGIES FOR INDUCTION OF BROAD NEUTRALIZING ANTIBODIES FOLLOWING VACCINATION: Edited by Ralf WagnerParticle-based delivery of the HIV envelope proteinAsbach, Benedikta; Wagner, Ralfa,bAuthor Information aMolecular Microbiology (Virology), Institute of Medical Microbiology and Hygiene, Universität Regensburg bInstitute of Clinical Microbiology and Hygiene, University Hospital Regensburg, Regensburg, Bavaria, Germany Correspondence to Benedikt Asbach, Molecular Microbiology (Virology), Institute of Medical Microbiology and Hygiene, Universität Regensburg, Franz-Josef-Strauß-Allee 11, 93053 Regensburg, Bavaria, Germany. Tel: +49 941 944 6491; e-mail: email@example.com Current Opinion in HIV and AIDS: May 2017 - Volume 12 - Issue 3 - p 265-271 doi: 10.1097/COH.0000000000000366 Buy Metrics Abstract Purpose of review A major focus in HIV vaccine research is the development of suitable antigens that elicit broadly neutralizing antibody responses targeting HIV's envelope protein (Env). Delivery of Env in a repetitive manner on particle-based carriers allows higher avidity interactions and is therefore expected to efficiently engage B cells, thus leading to affinity maturation that results in superior antibody responses characterized by improved breadth, potency, and durability. This review summarizes current work that is evaluating diverse types of such particulate carriers for Env delivery. Recent findings Various types of particle scaffolds are being investigated, encompassing group-specific antigen-derived virus-like particles, bacteria-derived proteins that self-assemble into symmetrical nanoparticles, as well as liposomes assembled from membrane components and recombinantly produced Env isoforms. Env-derived antigens from peptides over selected isolates to improved, stabilized next-generation designer Envs have been attached to such carriers. Immunological evaluation in animal models showed that these structures often elicit superior humoral immune responses. Summary The findings reviewed here emphasize the potential of particle-based delivery modalities to elicit better antibody responses. Together with advances in Env antigen design, these approaches may synergistically act together on the way to obtain vaccine candidates that potentially induce protective immune responses against HIV. Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.